NIH-funded research R21 grant

Understanding how HIV behaves and evolves in structured populations

Official title: Description of HIV social behavior using a phylogenetic model of structured co-evolution

Funded at University of Louisville · NIH-11139567 · Data updated 2026-11-12

This study is looking at how HIV behaves in groups, like bacteria do, to understand how it survives even with treatment, and the findings could help develop better ways to manage HIV for patients.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of Louisville
NIH-funded
Lab location1 site (Louisville, United States)
Project startJuly 16, 2024
Project endMay 31, 2026
Funding year2025
Award (this year)$236,595
NIH project number5R21AI183992-02
Project IDNIH-11139567 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include individuals living with HIV who are experiencing challenges with treatment resistance.

Less likely to help

Patients who are not infected with HIV or those who have already achieved viral suppression may not receive direct benefits from this research.

What this research studies

This research investigates the complex social behaviors of HIV by examining how the virus interacts within structured populations, similar to bacterial communities. By using genomic sequencing, the study aims to uncover the evolutionary pathways that allow HIV to persist despite treatment efforts. The approach focuses on understanding the cooperative functions of different virus subgroups and how they adapt over time, which could lead to new therapeutic strategies for managing HIV infections. Patients may benefit from insights that could inform more effective treatments and interventions.

Why it matters

Potential benefit: If successful, this research could lead to novel therapeutic strategies that improve the management of HIV infections.

How similar studies have gone: Previous research has shown success in understanding viral behaviors through similar genomic approaches, indicating potential for impactful findings in this area.

Where this research is happening

  • University of Louisville
    Louisville, United States
    Active

Researchers

  • Principal investigator: Magalis, Brittany — University of Louisville
  • Study coordinator: Magalis, Brittany

Related research

Other NIH-funded projects on the same topics.

  • Gastric rhythm map to understand stomach problems using a new noninvasive tool

    A new noninvasive body surface mapping method is being tested to see if abnormal stomach electrical rhythms explain chronic stomach problems like functional dyspepsia and persistent nausea.

    NIH research University of Louisville · Louisville, United States · NIH-11611507

  • Novel antivirals for alphavirus arthritis

    A research team is refining a promising antiviral compound to treat alphavirus infections that cause arthritis, with a focus on Chikungunya and related viruses.

    NIH research University of Louisville · Louisville, United States · NIH-11609180

  • Linking heavy metal exposure to a tougher breast cancer type (TNBC)

    Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

    NIH research University of Louisville · Louisville, United States · NIH-11567535

  • Cardiac safety of flavored e-cigarette aerosols in adults

    A pharmacist or clinician would test how inhaling flavored e-cigarette aerosols affects heart rhythm in adults to see if flavors raise the risk of heart problems.

    NIH research University of Louisville · Louisville, United States · NIH-11541950

  • Biomedical Research Facilities to Expand Precision Medicine in Kentucky

    A large NIH grant aims to renovate and expand a shared precision medicine center in Kentucky to speed up research that could improve health for people in Appalachia and surrounding areas.

    NIH research University of Louisville · Louisville, United States · NIH-11523167

  • Rac-enhanced CAR-Macrophages against TNBC

    A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

    NIH research University of Louisville · Louisville, United States · NIH-11520503

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.